-
Mashup Score: 2Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study - Blood Cancer Journal - 2 year(s) ago
Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
The Mayo-2018 smoldering multiple myeloma (SMM) risk score is used routinely in the clinical setting but has only been validated at diagnosis. In SMM patients, the progression risk decreases over time. However, the utility of applying risk stratification models after diagnosis is unknown. We retrospectively studied 704 SMM patients and applied the Mayo 2018 and IMWG-2020 risk stratification…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
Assessing the prognostic utility of smoldering multiple myeloma [SMM] risk stratification scores applied serially post diagnosis [Nov 26, 2021] @VisramAlissa et al. @myelomaMD @MayoMyeloma @BloodCancerJnl https://t.co/V3jhpWvFAL #mmsm
-
-
Mashup Score: 43
Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of…
Source: Blood Cancer JournalCategories: Hematologists1, Latest HeadlinesTweet-
New consensus definition for primary plasma cell leukemia. 5% of plasma cell in peripheral blood. International Myeloma Working Group. Just online! @BloodCancerJnl @MayoMyeloma #gemmac @hospitalclinic @hematoclinicbcn @VincentRK @mvmateos https://t.co/Ny8CAIRytb
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage #mmsm https://t.co/GIYUKZTWkI
-
-
Mashup Score: 1
The Mayo-2018 smoldering multiple myeloma (SMM) risk score is used routinely in the clinical setting but has only been validated at diagnosis. In SMM patients, the progression risk decreases over time. However, the utility of applying risk stratification models after diagnosis is unknown. We retrospectively studied 704 SMM patients and applied the Mayo 2018 and IMWG-2020 risk stratification…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
Assessing the prognostic utility of smoldering multiple myeloma [SMM] risk stratification scores applied serially post diagnosis [Nov 26, 2021] @VisramAlissa et al. @myelomaMD @MayoMyeloma @BloodCancerJnl https://t.co/V3jhpWvFAL #mmsm https://t.co/xIDpheNs0c
-
-
Mashup Score: 7Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany - Blood Cancer Journal - 3 year(s) ago
Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in western countries. Therapy is indicated in symptomatic and advanced stages and has changed fundamentally since 2010 when rituximab, an anti-CD20 antibody, has been approved for treatment of CLL. Until then therapy had been based on chemotherapy drugs. This study investigates whether survival in CLL patients improved at…
Source: Blood Cancer JournalCategories: Hematologists1, Latest HeadlinesTweet-
Increased survival of patients with chronic lymphocytic #leukemia before and after the introduction of chemoimmunotherapy in Germany. Kajüter, H.,. et al. Blood Cancer J. 11, 174 (2021). https://t.co/PmmPpQjcb5 Good to see advances of therapy translated into improved survival. https://t.co/6AdGZZFGyQ
-
-
Mashup Score: 2Detection of minimal residual disease by next generation sequencing in AL amyloidosis - Blood Cancer Journal - 3 year(s) ago
Blood Cancer Journal –
Detection of minimal residual disease by next generation sequencing in AL… Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
@kansagraMD @CyclingDoctor Tough thing about using MRD in AL is that what limited evidence exists suggests that it may rarely be negative, but many MRD-positive patients do well long-term: https://t.co/4SENWQxT0k s/o @vsanchorawala
-
-
Mashup Score: 0CAR-T cell therapy: current limitations and potential strategies - Blood Cancer Journal - 3 year(s) ago
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
CAR-T cell therapy: current limitations and potential strategies | Blood Cancer Journal https://t.co/ufWN6twUXb
-
-
Mashup Score: 13CAR-T cell therapy: current limitations and potential strategies - Blood Cancer Journal - 3 year(s) ago
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
CAR-T therapy. Current limitations and strategies to overcome. Review Article. #OpenAccess #BCJ https://t.co/qmjW5GaqU0 https://t.co/ejCpe1VhlN
-
-
Mashup Score: 2Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype - Blood Cancer Journal - 3 year(s) ago
Normal karyotype in therapy-related acute myeloid leukemia (t-AML) is rare and the relative contribution of prior exposure to chemotherapy or radiotherapy to outcomes in these patients remains uncertain. We performed a retrospective study of 742 patients with newly diagnosed AML and normal karyotype (t-AML, n = 61, and non-t-AML, n = 681). Patients with t-AML were older but had a similar…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
@AaronGoodman33 https://t.co/UqSv2v59uI If death in remission is driving OS for diploid t-AML, my vote is the “lower intensity” option with VEN+HMA which NPM1m AML should be sensitive to, de novo or otherwise
-
-
Mashup Score: 2Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma - Blood Cancer Journal - 3 year(s) ago
Blood Cancer Journal –
Application of an ex-vivo drug sensitivity platform towards achieving complete… Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @adj_23: Currently writing up this work to follow up from our initial case report in @BloodCancerJnl - https://t.co/6rfZpNfHO0. Also see…
-
MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19. https://t.co/3ZD5sCWa5s #mmsm #USMRC #myeloma #MedEd #MedTwitter https://t.co/HsLVcwdznA